Lisofylline
- Generic Name
- Lisofylline
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N4O3
- CAS Number
- 100324-81-0
- Unique Ingredient Identifier
- L1F2Q2X956
- Background
Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.
Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 1
- Registration Number
- NCT01603121
- Locations
- 🇺🇸
Eastern Virginia Medical School Strelitz Diabetes Center, Norfolk, Virginia, United States
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- DiaKine Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT00896077
- Locations
- 🇺🇸
Advanced Biomedical Research, Inc. (ABR), Hackensack, New Jersey, United States
Strategies to Improve Islet Survival
Phase 2
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Procedure: Islet transplantDrug: Antithymocyte globulin
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2016-04-26
- Target Recruit Count
- 5
- Registration Number
- NCT00464555
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸University of Miami, Miami, Florida, United States
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)
Phase 3
Completed
- Conditions
- Respiratory Distress Syndrome, AdultLung Diseases
- Locations
- 🇺🇸
Baystate Medical Center, Springfield, Massachusetts, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Wake Forest University, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath